(Lymphoma) Ezharmia Launched for Sale in Japan
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- December 23, 2022
- Read time: 1 minute
On December 20, 2022, Daiichi Sankyo Co., Ltd. announced the launch of Ezharmia, a treatment drug for relapsed or refractory adult T-cell leukemia-lymphoma (ATL), available in 50 mg and 100 mg tablet formulations.
Adult T-cell leukemia-lymphoma is one of the common hematological malignancies in Japan, with approximately 1,000 new cases detected annually. It is known that ATL is caused by HTLV-1 infection, but no effective method or treatment to prevent its onset has been found.
This launch was based on results from a Phase II clinical trial conducted in Japan, enrolling relapsed or refractory ATL patients (N=25) treated with Ezharmia to evaluate safety and efficacy. The primary endpoint response rate was 48%, comprising 5 patients with complete remission, 37 patients with partial remission, and 10 patients with stable disease.
Additionally, based on the trial results, Ezalmia received designation as an orphan drug by the Ministry of Health, Labour and Welfare in November 2021 and received domestic manufacturing and marketing approval in Japan in September 2022.
Source: https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202212/20221220_J.pdf
- Clinical Trial Medications
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4